JAD1D Antibody - #DF2548

(3)   (9)  
Product: JAD1D Antibody
Catalog: DF2548
Description: Rabbit polyclonal antibody to JAD1D
Application: WB IHC
Cited expt.: WB, IHC
Reactivity: Human
Mol.Wt.: 174kDa; 174kD(Calculated).
Uniprot: Q9BY66
RRID: AB_2839754

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human
Clonality:
Polyclonal
Specificity:
JAD1D Antibody detects endogenous levels of total JAD1D.
RRID:
AB_2839754
Cite Format: Affinity Biosciences Cat# DF2548, RRID:AB_2839754.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

H-Y; Histocompatibility Y antigen; Histone demethylase JARID1D; HY; HYA; JAD1D; Jumonji AT rich interactive domain 1D (RBP2 like); Jumonji/ARID domain-containing protein 1D; KDM5D; KDM5D_HUMAN; KIAA0234; Lysine (K) specific demethylase 5D; Lysine demethylase 5D; Lysine-specific demethylase 5D; Protein SmcY; Selected mouse cDNA on Y human homolog of; SMC homolog Y chromosome; Smcy homolog Y linked;

Immunogens

Immunogen:

A synthesized peptide derived from human JAD1D, corresponding to a region within C-terminal amino acids.

Uniprot:

Q9BY66(KDM5D_HUMAN) >>Visit HPA database.

Gene(ID):
KDM5D(8284)
Expression:
Q9BY66 KDM5D_HUMAN:

Expression is highly down-regulated in metastatic prostate tumors.

Sequence:
MEPGCDEFLPPPECPVFEPSWAEFQDPLGYIAKIRPIAEKSGICKIRPPADWQPPFAVEVDNFRFTPRVQRLNELEAQTRVKLNYLDQIAKFWEIQGSSLKIPNVERKILDLYSLSKIVIEEGGYEAICKDRRWARVAQRLHYPPGKNIGSLLRSHYERIIYPYEMFQSGANHVQCNTHPFDNEVKDKEYKPHSIPLRQSVQPSKFSSYSRRAKRLQPDPEPTEEDIEKHPELKKLQIYGPGPKMMGLGLMAKDKDKTVHKKVTCPPTVTVKDEQSGGGNVSSTLLKQHLSLEPCTKTTMQLRKNHSSAQFIDSYICQVCSRGDEDDKLLFCDGCDDNYHIFCLLPPLPEIPRGIWRCPKCILAECKQPPEAFGFEQATQEYSLQSFGEMADSFKSDYFNMPVHMVPTELVEKEFWRLVSSIEEDVTVEYGADIHSKEFGSGFPVSNSKQNLSPEEKEYATSGWNLNVMPVLDQSVLCHINADISGMKVPWLYVGMVFSAFCWHIEDHWSYSINYLHWGEPKTWYGVPSLAAEHLEEVMKMLTPELFDSQPDLLHQLVTLMNPNTLMSHGVPVVRTNQCAGEFVITFPRAYHSGFNQGYNFAEAVNFCTADWLPAGRQCIEHYRRLRRYCVFSHEELICKMAAFPETLDLNLAVAVHKEMFIMVQEERRLRKALLEKGVTEAEREAFELLPDDERQCIKCKTTCFLSALACYDCPDGLVCLSHINDLCKCSSSRQYLRYRYTLDELPTMLHKLKIRAESFDTWANKVRVALEVEDGRKRSFEELRALESEARERRFPNSELLQRLKNCLSEVEACIAQVLGLVSGQVARMDTPQLTLTELRVLLEQMGSLPCAMHQIGDVKDVLEQVEAYQAEAREALATLPSSPGLLRSLLERGQQLGVEVPEAHQLQQQVEQAQWLDEVKQALAPSAHRGSLVIMQGLLVMGAKIASSPSVDKARAELQELLTIAERWEEKAHFCLEARQKHPPATLEAIIRETENIPVHLPNIQALKEALTKAQAWIADVDEIQNGDHYPCLDDLEGLVAVGRDLPVGLEELRQLELQVLTAHSWREKASKTFLKKNSCYTLLEVLCPCADAGSDSTKRSRWMEKALGLYQCDTELLGLSAQDLRDPGSVIVAFKEGEQKEKEGILQLRRTNSAKPSPLAPSLMASSPTSICVCGQVPAGVGVLQCDLCQDWFHGQCVSVPHLLTSPKPSLTSSPLLAWWEWDTKFLCPLCMRSRRPRLETILALLVALQRLPVRLPEGEALQCLTERAIGWQDRARKALASEDVTALLRQLAELRQQLQAKPRPEEASVYTSATACDPIREGSGNNISKVQGLLENGDSVTSPENMAPGKGSDLELLSSLLPQLTGPVLELPEAIRAPLEELMMEGDLLEVTLDENHSIWQLLQAGQPPDLDRIRTLLELEKFEHQGSRTRSRALERRRRRQKVDQGRNVENLVQQELQSKRARSSGIMSQVGREEEHYQEKADRENMFLTPSTDHSPFLKGNQNSLQHKDSGSSAACPSLMPLLQLSYSDEQQL

Research Backgrounds

Function:

Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'. Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-4'. May play a role in spermatogenesis. Involved in transcriptional repression of diverse metastasis-associated genes; in this function seems to cooperate with ZMYND8. Suppresses prostate cancer cell invasion. Regulates androgen receptor (AR) transcriptional activity by demethylating H3K4me3 active transcription marks.

Subcellular Location:

Nucleus.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expression is highly down-regulated in metastatic prostate tumors.

Family&Domains:

The JmjC domain is required for enzymatic activity.

Belongs to the JARID1 histone demethylase family.

References

1). JARID1D-dependent androgen receptor and JunD signaling activation of osteoclast differentiation inhibits prostate cancer bone metastasis through demethylating H3K4. Theranostics, 2025 (PubMed: 39816691) [IF=12.4]

Application: IHC    Species: human    Sample:

Figure 1. JARID1D downregulation is associated with PCa metastasis and poor prognosis. (A) JARID1D mRNA levels in PCa tissues were assessed by analyzing the GSE35988. (B and C) Kaplan-Meier analysis of disease-free survival (DFS) and overall survival (OS) curves for patients with PCa with low JARID1D expression vs. those with high JARID1D expression (log-rank test, n = 150). (D) Cell type annotation of 25782 cells using t-distributed stochastic neighbor embedding (t-SNE) and uniform manifold approximation and T-SNE plots showing average expression of gene markers for all cell clusters. (E) T-SNE plot of JARID1D showing normalized expression levels in the sub-clusters. (F) Gene Ontology (GO) enrichment analysis for JARID1D-high-and JARID1D-low-expression groups. (G) Quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis of the effect of JARID1D knockdown on the expression of invasiveness-associated genes. (H) Immunohistochemistry (IHC) analysis and quantification of JARID1D expression levels in clinical samples of primary prostate cancer (PCa), local metastatic PCa, and bone metastatic PCa. Scale bars, 50 and 20 μm.

Application: IF/ICC    Species: human    Sample:

Figure 5. H3K4 modification by JARID1D dynamically regulates AR transcription. (A) Quantitative RT-PCR was used to analyze AR, IL-6, and RANKL expression levels in 22RV1 Sh-JARID1D cells treated with Enz (B) Quantitative RT-PCR was used to analyze AR, IL-6, and RANKL expression levels in DU145 Sh-JARID1D cells treated with R1881. (C) Before protein blotting with mutual antibodies, anti-JARID1D, anti-AR, or control antibodies were used to perform Co-IP on 22RV1 cells grown in serum-containing medium;. (D) RT-PCR analysis of AR and JARID1D mRNA expression levels after transfection with si-RNA in 22RV1 and C42 cells. (E) Western blotting of AR and JARID1D protein expression levels after transfection with siRNA in 22RV1 and C42 cells; (F) mRNA expression level of NSE and CGA. (I, K, and M) Co-localization and expression changes of JARID1D and AR. JARID1D is labeled with red fluorescence, AR is labeled with green fluorescence and the cell nucleus is counterstained with DAPI (blue). (J, L, and N) Histone methylation levels at AR enhancer regions.

Application: WB    Species: human    Sample:

Figure 5. H3K4 modification by JARID1D dynamically regulates AR transcription. (A) Quantitative RT-PCR was used to analyze AR, IL-6, and RANKL expression levels in 22RV1 Sh-JARID1D cells treated with Enz (B) Quantitative RT-PCR was used to analyze AR, IL-6, and RANKL expression levels in DU145 Sh-JARID1D cells treated with R1881. (C) Before protein blotting with mutual antibodies, anti-JARID1D, anti-AR, or control antibodies were used to perform Co-IP on 22RV1 cells grown in serum-containing medium;. (D) RT-PCR analysis of AR and JARID1D mRNA expression levels after transfection with si-RNA in 22RV1 and C42 cells. (E) Western blotting of AR and JARID1D protein expression levels after transfection with siRNA in 22RV1 and C42 cells; (F) mRNA expression level of NSE and CGA. (I, K, and M) Co-localization and expression changes of JARID1D and AR. JARID1D is labeled with red fluorescence, AR is labeled with green fluorescence and the cell nucleus is counterstained with DAPI (blue). (J, L, and N) Histone methylation levels at AR enhancer regions.
2). Curcumin blunts epithelial-mesenchymal transition to alleviate invasion and metastasis of prostate cancer through the JARID1D demethylation. Cancer cell international, 2024 (PubMed: 39218854) [IF=5.8]

Application: WB    Species: Mouse    Sample: PCa cells

Fig. 1. Knocking down JARID1D can enhance the invasive ability of PCa cells. (A-B) The expression of JARID1D in PCa cell lines (22RV1, LNCaP, PC3, C4-2 and DU145) was analyzed using quantitative RT-PCR (A) and Western blot (B) and quantitative analysis results. (C-D) The expression of JARID1D after 22RV1 cells transfection into lentivirus was analyzed using Western blot and quantitative analysis results. (C) and quantitative RT-PCR (D). (E) Transwell (left) and its quantification (right) analyzed the changes in the invasion ability of the 22RV1 cells after knockdown of JARID1D when compared with the NC group, *P 

Application: IHC    Species: Mouse    Sample:

Fig. 5. Curcumin inhibits PCa lung metastasis caused by JARID1D knockdown through EMT in AR-dependent cells in vivo. (A-B) Bioluminescence image (left) and its quantification (right) of (A) whole mouse and (B) mouse lung tissue after treatment with curcumin. (C) H&E staining results of the mouse lung metastasis tumor tissue after curcumin treatment. (D) The body weight of mice treated with curcumin was monitored every two days. (E) The expression level of JARID1D, AR, MMP2, E-cadherin, N-cadherin, Vimentin in the lung metastasis model induced by the injection of 22RV1-JARID1D cells after treatment with curcumin. EMT, epithelial-mesenchymal transition; PCa, prostate cancer; AR, androgen receptor
3). KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients. Translational Andrology and Urology, 2021 (PubMed: 34804837) [IF=1.9]

Application: IHC    Species: Human    Sample:

Figure 1 Comparison of KDM5D expression in tumor cells (A) and benign cells (B) in radical prostatectomy specimens of docetaxel responders and non-responders. (C) Absolute number of Ki-67 index (% of positive cells in correlation to total cell number of evaluated area) in docetaxel responders and non-responders. Data presented as mean ± SEM, statistics: unpaired t-test, *, P

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.